



April 2021

Harbour BioMed **Journal**
Investor Relations

02142.HK

HARBOUR
BIOMED



CONTENTS


HBM Overview	01
2020 Significant Achievements	02
2020 Financial Strength	03
2021-2023 Outlook	04
Announcement and Notice	05
Company News Highlights	06
Global Market Overview	07
BioMed Industry	08

HBM (02142.HK)


Overview	
Website--Investor Access	https://www.harbourbiomed.com/investor
Market Cap (03/31, Mil HK\$)	6849.58
Total Share Capital (Mil)	767.89
Circulation Stock (Mil)	767.89

In early March, various stock indexes plummeted across the board on the Hong Kong stock market, including HSCI and HSHCI. From mid-March, stock indices rebounded in a volatile way. The closing price of HSHCI fell 8.34% on the last trading day. Harbour's stock price was under market pressure but still outperformed the market.

HBM Share Price in March



HSHCI in March



2020 Significant Achievements



Clinical Products

- **6 Clinical Trials:**
HBM9161 ITP, MG, NMOSD; HBM9036 DED; HBM4003 mono in Australia and combo with PD-1 in China
- **7 IND Approvals:**
including 4 for HBM4003, 2 for HBM9161 and 1 for HBM9022
- **1 Breakthrough Therapy Designation:**
HBM9161 MG



Pre-clinical Products

- **3 Monoclonal Antibodies:**
HBM1022(CCR8)、HBM1007(CD73)、HBM1029(Claudin18.2)
- **3 Bispecific Antibodies:**
HBM7008(TAA1X4-1BB)、HBM7015(PD-L1XTGF-β)、HBM7020(BCMAXCD3)
- **1 Co-Discovery:**
HBM9378



Global Collaboration

- **Abbvie:**
COVID-19 Neutralizing Antibody Out-license
- **Hualan Genetic:**
Strategic Co-Development & Out-license Collaboration
- **Vir Biotechnology:**
Strategic Co-Discovery Collaboration




Financial Strength


- **Revenue:**
14.1 million USD (+160% vs. 2019)
- **R&D Expenses:**
55.2 million USD (+12% vs.2019)
- **Cash and Bank Balances:**
356.8 million USD

2020 Financial Strength


Revenue




Other Income and Gains



R&D Expenses




Cash and Bank Balances



Note: in Mil USD

2021-2023 Outlook



Commercialization



Team assembled with launch experience and expertise at global and local level



Launch readiness efforts initiated – planning, tracking and assessment



Ongoing KOL engagement to identify and fill knowledge gaps

Announcement and Notice

On 29th March, the Company announced 2020 audited consolidated annual results, revenue for fiscal year 2020 reached \$14.1 million, increased by 160% year-on-year. Core clinical products made major progress including HBM4003, Batoclimab (HBM9161) and Tanfanercept (HBM9036). Multiple research products are coming close to clinical stage. The company continues to establish strategic partnership with worldwide industry partners to fully leverage the technology platforms, including out-licensing the global rights of COVID-19 neutralizing antibody to Abbvie, and collaborating with Vir Biotechnology and Hualan Genetic.

The company completed first patient dosing in an open phase I clinical study of anti-CTLA-4 antibody (HBM4003) for Chinese patients suffering from advanced melanoma and other solid tumors. This study will evaluate the safety, tolerability, PK/PD, and anti-tumor activity of HBM4003 in combination with PD-1 antibody in the treatment of solid tumors.

The company announced the first patient in the phase III clinical trial of Tanfanercept (HBM9036). The purpose of this trial is to evaluate the effectiveness and safety of Tanfanercept eye drops (0.25%) compared with placebo in the treatment of moderate-to-severe DED patients in China.

Company News Highlights

01

Full Year 2020 Annual Results press release distributed, achieved major progress in product research and revenue increased 160% year-on-year.

02

HBM has entered into a new phase of commercialization in the lifecycle with multiple assets in late-phase clinical trials. To lead this phase, the company has appointed Mai-Jing Liao, PhD, to the position of Chief Commercial Officer, Danny Wu, as Vice President and Head of Commercial Launch. They will be responsible for company's commercialization efforts including but not limited to launch readiness, sales and marketing that will catapult HBM into a new critical stage.

03

The company has been successfully enrolled into Shenzhen-Hong Kong Stock Connect, effective on 15th March 2021. Mainland investors can buy HBM shares through this mechanism.



Global Market Overview

Global Market Index			
	Closing Price		
	2021.03.01	2021.03.10	2021.03.31
Dow Jones Industrial Average	30932.37	31832.74	33066.96
NASDAQ Composite Index	13192.35	13073.82	13045.39
UK FTSE 100 Index	6483.43	6730.34	6772.12
German DAX Index	13786.29	14437.94	15008.61
France CAC40 Index	5703.22	5924.97	6088.04

HK Market Index			
	Closing Price		
	2021.03.01	2021.03.10	2021.03.31
HS Index	28892.86	28773.23	28577.50
HS Composite Index	4691.26	4485.71	4447.99
HS TECH	8954.44	8063.12	8180.32
HS China Enterprises Index	11247.21	10973.15	11020.87
HS Healthcare Index	7315.17	6361.00	6705.23

Global Economic Data (March)			
Country	Items	Forecast	Actual
USA	Richmond Fed Manufacturing Index	16	17
German	Manufacturing PMI	59.3	59
France	Manufacturing PMI	56.5	58.8
Eurozone	Manufacturing PMI	57.7	62.4
German	Manufacturing PMI	60.8	66.6
UK	Manufacturing PMI	55	57.9


- The initial value of US Market Manufacturing PMI increased to 59 in March
- The Eurozone Sentiment Index increased to 101, the highest since February last year
- US Consumer Confidence Index continued to increase in March, the highest since the epidemic in March last year
- German CPI increased to 1.7% in March, the highest since February last year
- China Manufacturing PMI increased to 51.9%, up 1.3% from previous month

BioMed Industry

Market Overview

On 31th March, HSCI closed at 4447.99, down 5.19% from the first trading day this month. HSHCI closed at 6705.23, down 8.34%, CESHKB closed at 12148.65, down 7.97%.

HK Listing BioMed Companies (18A)



Note: the axes are scaled on logarithm

HARBOUR BIOMED



Harbour BioMed

ir@harbourbiomed.com

www.harbourbiomed.com